Skip to main content
Journal cover image

Cost-Effectiveness of Treatment Strategies for Spinal Metastases.

Publication ,  Journal Article
Kowalchuk, RO; Mullikin, TC; Kim, DK; Morris, JM; Ebner, DK; Harmsen, WS; Merrell, KW; Beriwal, S; Waddle, MR; Kim, H
Published in: Pract Radiat Oncol
2022

PURPOSE: We analyzed the cost-effectiveness of standard palliative external beam radiation (EBRT, 8 Gy in 1 fraction), stereotactic body radiation therapy (SBRT, 24 Gy in 2 fractions), and radiofrequency ablation for painful spinal metastases. Single-fraction SBRT (delivering 24 Gy) was also assessed. METHODS AND MATERIALS: A Markov state transition model was constructed. Key model parameters were derived from prospective clinical trial data. Strategies were compared using the incremental cost-effectiveness ratio (ICER), with effectiveness in quality-adjusted life-years (QALYs) and a willingness-to-pay threshold of $100,000 per QALY gained. Costs included both hospital and professional costs using 2020 Medicare reimbursement. RESULTS: The base case demonstrated that 2-fraction SBRT was not cost-effective compared with single-fraction EBRT, with an ICER of $194,145 per QALY gained. Radiofrequency ablation was a more costly and less effective strategy in this model. Probabilistic sensitivity analysis demonstrated that EBRT was favored in 66% of model iterations. If median survival were improved after SBRT, 2-fraction SBRT became cost-effective, with ICERs of $80,394, $57,062, and $47,038 for 3-, 6-, and 9-month improvements in survival, respectively. Because 2-fraction SBRT data reported that 18% of patients had an indeterminant pain response at 3 months and 2-fraction SBRT is infrequently used in clinical practice, single-fraction SBRT data were also assessed. Single-fraction SBRT delivering 24 Gy was cost-effective compared with single-fraction EBRT, with an ICER of $92,833 per QALY gained. CONCLUSIONS: For appropriately chosen patients, single-fraction SBRT was more cost-effective than conventional EBRT or radiofrequency ablation. Conventional EBRT remains a cost-effective treatment for patients with poor expected survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pract Radiat Oncol

DOI

EISSN

1879-8519

Publication Date

2022

Volume

12

Issue

3

Start / End Page

236 / 244

Location

United States

Related Subject Headings

  • United States
  • Spinal Neoplasms
  • Radiosurgery
  • Prospective Studies
  • Medicare
  • Humans
  • Cost-Benefit Analysis
  • Aged
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kowalchuk, R. O., Mullikin, T. C., Kim, D. K., Morris, J. M., Ebner, D. K., Harmsen, W. S., … Kim, H. (2022). Cost-Effectiveness of Treatment Strategies for Spinal Metastases. Pract Radiat Oncol, 12(3), 236–244. https://doi.org/10.1016/j.prro.2021.12.012
Kowalchuk, Roman O., Trey C. Mullikin, Dong Kun Kim, Jonathan M. Morris, Daniel K. Ebner, William S. Harmsen, Kenneth W. Merrell, Sushil Beriwal, Mark R. Waddle, and Hayeon Kim. “Cost-Effectiveness of Treatment Strategies for Spinal Metastases.Pract Radiat Oncol 12, no. 3 (2022): 236–44. https://doi.org/10.1016/j.prro.2021.12.012.
Kowalchuk RO, Mullikin TC, Kim DK, Morris JM, Ebner DK, Harmsen WS, et al. Cost-Effectiveness of Treatment Strategies for Spinal Metastases. Pract Radiat Oncol. 2022;12(3):236–44.
Kowalchuk, Roman O., et al. “Cost-Effectiveness of Treatment Strategies for Spinal Metastases.Pract Radiat Oncol, vol. 12, no. 3, 2022, pp. 236–44. Pubmed, doi:10.1016/j.prro.2021.12.012.
Kowalchuk RO, Mullikin TC, Kim DK, Morris JM, Ebner DK, Harmsen WS, Merrell KW, Beriwal S, Waddle MR, Kim H. Cost-Effectiveness of Treatment Strategies for Spinal Metastases. Pract Radiat Oncol. 2022;12(3):236–244.
Journal cover image

Published In

Pract Radiat Oncol

DOI

EISSN

1879-8519

Publication Date

2022

Volume

12

Issue

3

Start / End Page

236 / 244

Location

United States

Related Subject Headings

  • United States
  • Spinal Neoplasms
  • Radiosurgery
  • Prospective Studies
  • Medicare
  • Humans
  • Cost-Benefit Analysis
  • Aged
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences